{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:14:09Z","timestamp":1770974049944,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1124\/dmd.112.045302","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T02:57:34Z","timestamp":1338346654000},"page":"1686-1697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs"],"prefix":"10.1016","volume":"40","author":[{"given":"Robert L.","family":"Walsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran F.","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Helal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theunis C.","family":"Goosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Zientek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.045302_bib1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/FTD.0b013e3181f3c063","article-title":"A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients","volume":"32","author":"Barry","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.112.045302_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/138920006776359329","article-title":"A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment","volume":"7","author":"Bu","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.045302_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0090-9556(25)06011-8","article-title":"SKF 525-A inhibition, induction, and 452-nm complex formation","volume":"4","author":"Buening","year":"1976","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.112.045302_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0090-9556(25)06658-9","article-title":"Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion","volume":"23","author":"Crowley","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200645010-00002","article-title":"Significance of the minor cytochrome P450 3A isoforms","volume":"45","author":"Daly","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.112.045302_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0009-2797(84)90162-5","article-title":"The cytochrome P-450 metabolite complex derived from troleandomycin: properties in vitro and stability in vivo","volume":"51","author":"Delaforge","year":"1984","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.112.045302_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2174\/138920010794233503","article-title":"Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution","volume":"11","author":"Emoto","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.045302_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/dmd.111.038505","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction","volume":"39","author":"Foti","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/00498257109112269","article-title":"The enzymic formation of methylenedioxyphenyl derivative exhibiting an isocyanide-like spectrum with reduced cytochrome P-450 in hepatic microsomes","volume":"1","author":"Franklin","year":"1971","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.045302_bib12","first-page":"227","article-title":"Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes","volume":"2","author":"Franklin","year":"1977","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.112.045302_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00228-007-0365-6","article-title":"Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation","volume":"63","author":"Fromm","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045302_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.tpj.6500218","article-title":"CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers","volume":"4","author":"Fukuda","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.112.045302_bib15","series-title":"9th International ISSX Meeting, Online Abstracts; 2010 Sept 4\u20138; Istanbul, Turkey. Suppl 5, No 2","article-title":"Influence of CYP3A5 genotype on CP-945,598 pharmacokinetics and weight loss in the treatment of obese subjects","author":"Goosen","year":"2010"},{"key":"10.1124\/dmd.112.045302_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1208\/s12248-008-9019-6","article-title":"Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates","volume":"10","author":"Harper","year":"2008","journal-title":"AAPS J"},{"key":"10.1124\/dmd.112.045302_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0090-9556(25)06773-X","article-title":"Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450","volume":"15","author":"Hoag","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.clpt.6100208","article-title":"Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects","volume":"82","author":"Jin","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.045302_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1124\/dmd.106.010579","article-title":"Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine","volume":"34","author":"Jushchyshyn","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jps.22255","article-title":"Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection","volume":"100","author":"Kawakami","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.112.045302_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1124\/dmd.30.9.985","article-title":"Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4","volume":"30","author":"Khan","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","article-title":"Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam","volume":"82","author":"Kharasch","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.045302_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.112.045302_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/dmd.110.034074","article-title":"Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/03602530701690374","article-title":"Drugs as CYP3A probes, inducers, and inhibitors","volume":"39","author":"Liu","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.112.045302_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/138920008783331121","article-title":"Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5","volume":"9","author":"Niwa","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.045302_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib28","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.112.045302_bib29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/S0021-9258(20)82245-5","article-title":"The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties","volume":"239","author":"Omura","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.112.045302_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-9556(25)07631-7","article-title":"Selective mechanism-based inactivation of the major phenobarbital-inducible P-450 cytochrome from rabbit liver by phencyclidine and its oxidation product, the iminium compound","volume":"17","author":"Osawa","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045302_bib32","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/tx700207u","article-title":"Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates","volume":"20","author":"Pearson","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045302_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.112.045302_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Disc"},{"key":"10.1124\/dmd.112.045302_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.112.045302_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498259509061892","article-title":"Haemoprotein-mediated metabolism of enamines and the possible involvement of one-electron oxidations","volume":"25","author":"Sayre","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.045302_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0163-7258(81)90075-9","article-title":"Substrate interaction with cytochrome P-450","volume":"12","author":"Schenkman","year":"1981","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.112.045302_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/dmd.105.007047","article-title":"Selective pathways for the metabolism of phencyclidine by cytochrome p450 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts","volume":"34","author":"Shebley","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045302_bib40","series-title":"Mechanism-Based Enzyme Inactivators","author":"Silverman","year":"1995"},{"key":"10.1124\/dmd.112.045302_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.fpc.0000171516.84139.89","article-title":"CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele","volume":"15","author":"Sim","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.112.045302_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/00498250500446208","article-title":"Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5","volume":"36","author":"Soars","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.045302_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3A","volume":"38","author":"Thummel","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.112.045302_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.045302_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.112.045302_bib47","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045302_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.112.045302_bib49","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1016\/S0021-9258(17)33166-6","article-title":"Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography","volume":"251","author":"Yasukochi","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.112.045302_bib50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/tpj.2010.26","article-title":"The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis","volume":"11","author":"Zhu","year":"2011","journal-title":"Pharmacogenomics J"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.045302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:12:44Z","timestamp":1739909564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624227768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090955624227768"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.045302","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.045302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}